Savara Inc Number of Reportable Segments
Savara Inc (SVRA) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-11
- Savara Inc number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Savara Inc number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- Savara Inc number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Savara Inc number of reportable segments for fiscal 2024 was 1.00 Segment.
- Savara Inc number of reportable segments for fiscal 2016 was 1.00 Segment, a 0.00% change from fiscal 2015.
- Savara Inc number of reportable segments for fiscal 2015 was 1.00 Segment, a 0.00% change from fiscal 2014.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-13 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-27 | |||
| 2016-12-31 | 1.00 Segment 10-K · filed 2017-03-06 | |||
| 2015-12-31 | 1.00 Segment 10-K · filed 2016-03-14 | |||
| 2014-12-31 | 1.00 Segment 10-K · filed 2015-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |